Opioid Settlements: “Cash Cow”
“It’s heartbreaking to see what the government is doing with this money. Putting it in places they really don’t need ...
What’s Next for the Obesity Industrial Complex
The future of the obesity industry is not in novel drugs or new forms of therapy, but in combining existing ...
Black Swans of Health Policy
Don’t worry about the healthcare laws. Worry about the changing legal interpretations of existing healthcare laws.
Make the Patient Encounter a Conversation
The patient encounter, the heart of healthcare, is unique in its speed and complexity, unlike any other setting found in ...
What’s in Store for 2024?
Daily Remedy has new features launching in 2024 to enhance the patient experience and cultivate educational opportunities for physicians.
Physician Resilience Isn’t Just Will Power
In my work, I have learned one lesson over and over: resilience training alone is not sufficient to rein in ...
Achieve Success with Dry January
Setting goals and making resolutions for the new year is something that many people do. However these goals are forgotten ...
Gun Education is Harm Reduction
As a former marine and emergency medicine physician, I bring a unique perspective on gun control and ownership.
Not All Disabilities are Visible
Navigating the world as a disabled person is not easy, even with the ADA compliance regulations put in place.
Automation of Healthcare Documentation – a Blessing or Pandora’s Box?
The documentation-free, touch-free, human-free future of healthcare will come with its own set of unique stressors.
We May Soon Have a Nitazene Crisis
A drug testing service reported that, since September, nitazenes were found in 20 samples of black market benzodiazepines.
Addiction Isn’t Just Genetic
The impact of behavioral factors on addiction is a complex and multifaceted topic that continues to be researched and explored.
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more